Who is sponsoring NCT00228462?

NCT00228462 is sponsored by AstraZeneca.

What condition does NCT00228462 study?

NCT00228462 studies Schizophrenia.

What drugs are being tested in NCT00228462?

Interventions: Seroquel (quetiapine).

What is the status of NCT00228462?

NCT00228462 is currently COMPLETED.

Last reviewed 2013-01-03 · How we verify

A 1-year, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Phase 3 Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Sustained-release Quetiapine Fumarate (SEROQUEL) or Placebo (Abbreviated)

NCT00228462 Phase 3 COMPLETED

This study is being carried out to see if quetiapine (Seroquel) is effective in preventing patients from a schizophrenic relapse when studied for a long time (1 year) and if so, how it compares with non-active treatment.

Details

Lead sponsor	AstraZeneca
Phase	Phase 3
Status	COMPLETED
Enrolment	197
Start date	2005-03
Completion	2006-04

Conditions

Schizophrenia

Interventions

Seroquel (quetiapine)

Primary outcomes

The primary objective in this study is to demonstrate superior efficacy of quetiapine to placebo by evaluating relapse prevention in long-term use in patients with schizophrenia as measured by the time to first psychiatric relapse up to one year

Countries

Bulgaria, Poland